Related Experiment Video
Updated: Aug 6, 2026
Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
Clinical Research Abstracts of the British Equine Veterinary Association Congress 2015
Reasons For Performing Study:
New therapeutic strategies to modulate immune responses in human and equine allergic airway diseases are under extensive investigation. Stimulation of Treg cells with immune modulating agents is a novel therapeutic option.
Objectives:
The aim of this field study was to compare the effects of a nebulised nanoparticulate CpG immunotherapy (CpG-GNP) with and without specific allergens.
Study Design:
Longitudinal clinical study comparing 2 therapeutic options.
Methods:
Twenty RAO-affected horses were divided into 2 treatment groups (CpG alone and CpG with allergens). Two specific allergens were selected for each horse according to anamnesis and a functional in vitro test. Treatments were given by nebulisation 7 times and the horses were examined 3 times: baseline (I), after the treatment course (II), and after 6 weeks later (III). Clinical parameters, indirect intrapleural measurement, arterial blood gas, amount of tracheal mucus and neutrophil percentage were evaluated.
Results:
CpG alone resulted in a significant improvement in clinical parameters and a significant reduction of tracheal mucus after treatment and at 6 weeks post treatment. After CpG plus specific allergens, there was significant improvement of 70% of examined parameters. However, there were no significant differences in the results compared with CpG-GNP treatment alone.
Conclusions:
There were no significant differences between treatment groups. CpG-GNP immunotherapy alone produced a potent and persistent effect on allergic and inflammatory parameters and may have potential as for treatment of equine and human allergic inflammatory airway diseases. Ethical animal research: The study was approved by the regional legal agency for animal experiments of the Government of Bavaria, Germany (No. 55.2-1-54-2531-31-10). Owners gave informed consent for their horses' inclusion in the study. Sources of funding: Partly supported by the Deutsche Forschungsgemeinschaft (DFG) (Germany) (GE'2044/4-1). The AeroNeb Go™ vibrating mesh nebuliser (Aerogen, Galway, Ireland) was sponsored by Inspiration Medical (Bochum, Germany). Competing interests: None declared.
